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One of the presumed reasons for the lack of clinical 
activity of topical methotrexate in psoriasis is insuffi-
cient percutaneous penetration necessary to inhibit epi-
dermal DNA synthesis. The present study was under-
taken to select a vehicle to optimize penetration ofmeth-
otrexate in vitro and to determine the effects of this 
topical formulation on epidermal DNA synthesis in vivo 
in hairless mouse skin. 
Increased penetration of methotrexate was obtained 
in human skin in vitro with Vehicle N compared to water 
and n-decylrnethylsulfoxide vehicles. Repeated topical 
application of this methotrexate/Vehicle N preparation 
produced marked epidermal atrophy in treated sites in 
both normal and hyperproliferative essential fatty acid 
deficient hairless mouse skin without similat· effects at 
a distant skin site. Local inhibition of epidermal DNA 
synthesis was also obtained without systemic effects at 
a distant site. These studies demonstrate that metho-
trexate in Vehicle N may produce a direct effect on 
epidermis which may be useful for the topical therapy of 
psoriasis. 
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Methotrexate (MTX) has been used successfully for the 
systemic treatment of widespread severe psoriasis, but the risk 
of short-term and long-term effects has precluded the use of 
this dl'Ug for the great majority of patients with minimal p 0-
riasis [1]. Clinical trials of topical methotrexate therapy in an 
effort to circumvent systemic toxicity, have been uniformly 
disappointing [2-5], despite data which suggest that methotrex-
ate acts directly on the psoriatic plaque rather than systemically 
at a distant site [6,7). Other studies show that topical metho-
trexate preparations produce negligible percutaneous penetra-
tion of human skin in vitro [8] and in vivo [9,10] and thus 
suggest that the drug is not delivered to the proliferative 
epidermal cells where it is thought to act. 
In an effort to develop a topical ly effective methotrexate 
preparation for psoriasis, these studies were designed to test 
various vehicles to enhance methotrexate percutaneous pene-
tration in vitro and to evaluate the effect of these topical 
methotrexate formulation on epidermal DNA synthesis in 
hairless mice in vivo. 
MA TERIALS AND METHODS 
MethoLrexaLe was obtained fTom Lederle LaboraLories, Pearl River , 
New York, t1U'ough the courtesy of Dr. J. Birnbaum. MeLhot.rexate 
(3 ',5',7-"H) sodium (250 mCi/mmole) was obtained from Amersham 
and prjor to use was purified by chromatography on thin-layer cellulose 
plates in 0.006 M potassium phosphate buffer, pH 6.0. Deoxyuridine 
(6-"H) (25 Ci/mmole) was obtained from New England Nuclear, n-
decylmethylsulfoxide from Cyclo Chemical, and Veh icle N (alcohol 
47.5%, water, laureth-4, isopropylalcohol 4%, propylene glycol) from 
Neutrogena CorporaLion. 
In Vitro Percutan.eous Pelletration Assay 
T he percutaneous peneLration of methoLrexate was measured in 
glass diffu ion ce lls as previou Iy described [81. Exci ed human skin 
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CIOMSO (2.5%) 12 ± 10 
Vehicle N 50 ± 11 
" Mean values ± SD for 4 diffusion chambers. 
/, Samples taken after 48 hI incubations. 




0.06 15 ± 5 
0.12 36 ± 28 
0.50 124 ± 10 
obtained from abdominoplasty was used for these studies. 0.5 ml 
containing 10 j.lCi methotrexate-"H and cold methotrexate to give a 
final concentration of 2% in various vehicles was applied to the epider-
mal surface (0.2 ml/cm") . A total of 10 mg methotrexate was applied to 
each diffusion cell. T he dermal reservoir contained phosphate buffered 
saline. Three diffusion cells were run for each vehicle. Diffusion cells 
were incubated with constant stirring at 28°C. Methotrexate penetra-
tion was fo llowed at various time points up to 48 hI' by liquid scintilla-
tion coun ting. The test solu tion was removed after the 48-hr incubation 
period and the epidermal surface was r insed 3 times with vehicle in 
which the drug being tested was dissolved. This process effectively 
removed all drug which had not penetrated in to the stratum corneum. 
The epidermis was separated by heating the skin for 1 min on a hot 
plate at 60°C. Methotrexate was extracted from the epidermis a nd 
dermis utilizing the technique described by Werkheiser, Zakrzewski, 
and Nichol Ell] which specifically dissociates methotrexate fro m cel-
lular bound proteins. The stratum corneum was removed by repeated 
stripping with ceUophane tape until the skin glistened. 
Tn Vivo Studies 
HHS/J a lbino hairless mice age 2-3 mo were used for these ex peri -
ments. For induction of essential fatty ac id deficiency, 3-week-old 
animals were fed an essel')tial fatty acid defi cient d iet (Teklad) for 60 
days. 
Topical methotrexate preparations at various concentrations or ve-
hicle control 0.05 ml were applied to the back skin area of 1.5 cm x 3 
cm daily x 1 or X 3. S ix to 10 mice were used for each treatment group. 
Tritiated deoxYUl'idine was utilized as a precursor for assaying the effect 
of methotrexate on the de novo pathway for epidermal DNA synthesis. 
The incorporation of tritiated deoxyuridine in to DNA depends on the 
normal func:ioning of dihydrofolate reductase which is blocked by 
methotrexate. At selected time points a fter single or repeated topical 
methotrexate applications, mice were injected IP with trit iated deoxy-
uridine (50-100 j.lCi) for measurement of epidermal DNA synthesis in 
treated back skin to determine the local effect of methotrexate. DNA 
synthesis was simultaneously measured in un t reated abdominal skin of 
Vehicle N a nd methotrexate treated animals to determine systemic 
effects of methotrexate at a distant site. One hour after administration 
of isotope, anima ls were sacrificed by cervical dislocation and treated 
back skin and untreated abdominal skin was obtained. E pidermis was 
removed afte r incubating the skin specimens for 1 hI' at 37°C in 2 M 
sodium bromide. DNA was extracted and assayed using the technique 
described by Halprin [12]. Hesults of epidermal DNA synthesis were 
calculated as counts per minute per microgram of DNA. The effects of 
methotrexate treatment on DNA synthesis on the back and abdomen 
were expressed as percent of DNA synthesis in Vehicle N treated back 
skin and untreated abdomen in control animals. 
RESULTS 
In Vitro Percutaneous Penetration Studies 
There was a significant increase in methotrexate penetration 
at both 24 and 48 hr in Vehicle' N as compared with water (p 
< 0.01) and n-decylrnethylsulfoxide (p < 0.01) (Table). Vehicle 
N also produced a slight increase in epidermal methotre'xate 
content compared to the other vehicles. 
In Vivo Studies 
Three consecutive applications of Vehicle N in normal hair-
less mice control anilnals unexpectedly produced epidermal 
hyperplasia characterized by exfoliation, acanthosis, and hy-
Drug Content".1· 
Stratulll Corneum Epidermis 
%" M %" r·g 01 " 10 
0.15 9±5 0.09 0.1 ± 0 0.001 
0.36 21 ± 5 0.21 0.8 ± 0.3 0.008 
1.24 16 ± 8 O.Hi 1.5 ± 0.5 0.0] 
pergranulosis (Fig lA). Three daily applications of 2% metho-
trexate in Vehicle N to both normal (Fig 1) and hyperprolifer-
ative essential fatty acid deficient (Fig 2) hairless mouse skin 
produced marked epidermal atrophy in the areas where it was 
applied, without similarly affecting untreated abdominal skin. 
Three daily applications of 2% methotrexate in Vehicle N 
suppressed epidermal DNA synthesis 50% and 75% in treated 
back skin compared to the Vehicle N treated control, at 54 and 
72 hr respectively (Fig 3). In this experiment no significant (p 
< 0.001) systemic methotrexate effect was seen in the untreated 
abdominal skin at 54lu- (6 hl' after the last treatment). However, 
by 72 hr (24 hr after the last treatment) both local and systemic 
effects were obtained. Four daily applications of methotrexate 
resulted in total suppression of DNA synthesis in both the back 
skin and in the untreated abdominal skin (Fig 3). 
Three daily applications of 1% methotrexate in Vehicle N 
also produced inhibition of DNA synthesis in treated skin 6 hI' 
after the last treatment, while lower concentrations had no 
local or systemic effect (Fig 4). Topical methotrexate (0.5%) in 
n-decylmethylsulfoxide likewise had no effect on epidermal 
DNA synthesis in this model (Fig 4). 
DISCUSSION 
Since the topical use of methotrexate in psoriasis has not 
been successful , one of the theories postulated has been that 
the therapeutic effect of methotrexate is due to action at a site 
other than in the skin [4]. No evidence to support this theory 
has been found. However, since methotrexate can produce the 
same biologic and biochemical effects in psoriatic epidermis 
with intralesional [7] and systemic administration [6], it may 
be inferred that the therapeutic response is mediated by loca l 
chemotherapeutic activity in skin. Other factors should be 
considered as causes for failure of topical antimetabolite ther-
apy, such as inadequa te percutaneous absorption or lack of 
extended tissue-drug contact as would be expected with circu-
lating drug after systemic administration. Insofar as a vehicle 
is a factor in percutaneous penetration of a drug, we have shown 
in the present study that Vehicle N substantially enhances 
methotrexate penetration compared to n-decylrnethylsulfoxide 
and water vehicles. In view of previous data by Weinstein, 
Goldfaden, and Frost [6] showing that an intradermal dose of 
methotrexa te of 1 ~g/O.l ml results in a 50% inhibition of DNA 
synthesis in psoriatic cells, it would appear that the epidermal 
methotrexate concentrations obtained with Vehicle N are ap-
proaching levels sufficient for pharmacologic activity in pso-
riatic epidermis. Although penetration of methotrexate through 
psoriatic epidermis has not been determined, the inferior barrier 
of hyperproliferative skin [13] may facilitate increased penetra-
tion necessary to produce a therapeutic effect. 
Epidermal DNA synthesis in the normal and essential fatty 
acid defi cient hairless mouse has been a useful bioassay for 
topical chemotherapeutic drug activity in psoriasis [14,15]' 
T esting of the topical methotrexate/n-decylmethylsulfoxide 
preparation, previously shown to lack clinical activity in pso-
riasis [5] had no effect on epidermal DNA synthesis in the 
hairless mouse model (Fig 4) . In this model methotrexate in 
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F IG 1. Effects of topica l 2% methotrexate in normal hairless mice in 
Vehicle N on treated back and untreated abdomen skin. Methotrexate 
or Vehicle N applied daily x 3. Vehicle N control: (A) treated back; (E) 
un treated abdomen. Two percent methotrexate: (C) treated back; (D) 
untreated abdomen. 
Vehicle N inhibited DNA synt hesis in treated skin, without a 
significant effect on distant skin, 6 hI' after t he third application. 
A single dTUg application was ineffective. This may refl ect 
either the slow time course of penetration or the extended time 
period of tissue-drug contact necessar y to achieve a biochemica l 
effect. Twenty-foul' homs after the t hird application, DNA 
synthesis was inhibited at both the treated a nd distant skin 
sites. This presumably was due to the entry of methotrexate 
. ' 
FIG 2. Effects of topical 2% methotrexate in Vehicle N on treated 
back and untreated abdomen skin in essential ratty acid deficie nt 
hairless mice. Methotrexate or Vehicle N applied daily x 3. Vehicle N 
control: (A) treated back; (E) untreated abdomen. Two percent meth-
otrexate: (C) treated back; (D) untreated abdomen. 
into the systemic circulation at levels sufficient to inhibit DNA 
synthesis at a distant site. 
Ideally, further studies will r eveal an appropriate dose sched-
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FIG 3. Local and systemic effects of topical 2% methotrexate in 
Vehicle N on epidermal DNA synthesis in norma l hairless mice. Drugs 
or Vehicle N was applied to the back skin as indicated. R esults are 
expressed as percent of DNA synthesis in control a nima ls treated with 
Vehicle N. 
patients such tha t a local therapeutic effect can be achieved 
without risk of systemic toxicity. 
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FIG 4. E ffect of methotrexate concentration in Vehicle N a nd n-
decylmethylsu lfoxide on epidermal DNA synthesis in normal hairless 
mice. Drugs or veh icles were applied da ily X 3. Skin specimens were 
analyzed for DNA synthesis 6 hr after the last application. 
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